Total Payments
$568,657
2024 Payments
$107,303
Companies
37
Transactions
575
Medicare Patients
881
Medicare Billing
$110,923
Payment Breakdown by Category
Consulting$329,572 (58.0%)
Other$170,479 (30.0%)
Travel$40,867 (7.2%)
Food & Beverage$15,915 (2.8%)
Research$11,797 (2.1%)
Education$27.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $329,572 | 137 | 58.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $164,529 | 68 | 28.9% |
| Travel and Lodging | $40,867 | 91 | 7.2% |
| Food and Beverage | $15,915 | 269 | 2.8% |
| Unspecified | $11,797 | 7 | 2.1% |
| Honoraria | $5,950 | 2 | 1.0% |
| Education | $27.00 | 1 | 0.0% |
Payments by Type
General
$556,860
568 transactions
Research
$11,797
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $125,243 | 128 | $0 (2024) |
| Kite Pharma, Inc. | $56,277 | 27 | $0 (2024) |
| Celgene Corporation | $54,834 | 48 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $44,054 | 19 | $0 (2024) |
| Lilly USA, LLC | $40,959 | 20 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $37,815 | 54 | $0 (2023) |
| Genentech USA, Inc. | $34,162 | 43 | $0 (2024) |
| Janssen Biotech, Inc. | $23,347 | 61 | $0 (2023) |
| ADC Therapeutics America, Inc. | $22,187 | 33 | $0 (2024) |
| AstraZeneca UK Limited | $21,549 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $107,303 | 101 | E.R. Squibb & Sons, L.L.C. ($24,085) |
| 2023 | $79,195 | 88 | Lilly USA, LLC ($22,435) |
| 2022 | $65,235 | 63 | ADC Therapeutics America, Inc. ($14,370) |
| 2021 | $70,051 | 53 | Kite Pharma, Inc. ($18,360) |
| 2020 | $62,916 | 48 | AstraZeneca Pharmaceuticals LP ($24,731) |
| 2019 | $99,476 | 121 | Celgene Corporation ($25,789) |
| 2018 | $76,230 | 92 | AstraZeneca Pharmaceuticals LP ($36,663) |
| 2017 | $8,252 | 9 | Millennium Pharmaceuticals, Inc. ($7,859) |
All Payment Transactions
575 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: Oncology | ||||||
| 12/23/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: Oncology | ||||||
| 12/20/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,460.00 | General |
| Category: Oncology | ||||||
| 12/18/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $27.90 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.69 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $113.14 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | In-kind items and services | $112.00 | General |
| Category: Oncology | ||||||
| 12/08/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 12/08/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $117.78 | General |
| Category: BioOncology | ||||||
| 12/08/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $82.95 | General |
| 12/08/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $55.00 | General |
| 12/07/2024 | Eli Lilly and Company | JAYPIRCA (Drug) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: Oncology | ||||||
| 12/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $124.17 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $30.01 | General |
| 12/05/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $141.29 | General |
| Category: Oncology | ||||||
| 11/26/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $4,110.00 | General |
| Category: Oncology | ||||||
| 11/25/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $49.00 | General |
| 11/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Stivarga, Vitrakvi | Food and Beverage | In-kind items and services | $13.36 | General |
| Category: Oncology | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,865.00 | General |
| 11/21/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $34.22 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $9,550.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Millennium Pharmaceuticals, Inc. | $7,841 | 1 |
| TRILLIUM CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,880 | 2 |
| MULTI PRODUCT MAPLIRPACEPT ONTORPACEPT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| ONTORPACEPT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $660.00 | 2 |
| Phase I/II Study Of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine And Prednisone (R2CHOP) Chemoimmunotherapy In Patients With Newly Diagnosed Diffuse Large Cell And Follicular Grade IIIA/B B Cell Lymphoma (RV-NHL-PI-0325) | Celgene Corporation | $476.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 225 | 347 | $91,515 | $26,449 |
| 2022 | 6 | 234 | 361 | $93,302 | $27,863 |
| 2021 | 5 | 222 | 400 | $103,214 | $32,747 |
| 2020 | 6 | 200 | 342 | $89,063 | $23,865 |
Total Patients
881
Total Services
1,450
Medicare Billing
$110,923
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 39 | 90 | $31,680 | $10,616 | 33.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 70 | 109 | $27,359 | $7,628 | 27.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 71 | 96 | $18,624 | $4,418 | 23.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 24 | 24 | $11,304 | $3,083 | 27.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 21 | 28 | $2,548 | $703.47 | 27.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 52 | 85 | $29,920 | $10,158 | 33.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 70 | 126 | $31,626 | $9,438 | 29.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 70 | 95 | $18,430 | $4,231 | 23.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 16 | 16 | $7,536 | $2,204 | 29.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 23 | $4,462 | $1,394 | 31.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 15 | 16 | $1,328 | $437.68 | 33.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 70 | 154 | $38,654 | $12,412 | 32.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 40 | 75 | $26,400 | $9,173 | 34.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 81 | 130 | $25,220 | $6,979 | 27.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 18 | 18 | $8,478 | $2,750 | 32.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 13 | 23 | $4,462 | $1,433 | 32.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 55 | 105 | $25,095 | $6,576 | 26.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 34 | 57 | $19,095 | $5,000 | 26.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 64 | 100 | $18,500 | $3,742 | 20.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 21 | 21 | $9,429 | $3,116 | 33.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 14 | 18 | $9,072 | $2,833 | 31.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 12 | 41 | $7,872 | $2,598 | 33.0% |
About Dr. Krish Patel, M.D
Dr. Krish Patel, M.D is a Hematology & Oncology healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/28/2009. The National Provider Identifier (NPI) number assigned to this provider is 1346484821.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Krish Patel, M.D has received a total of $568,657 in payments from pharmaceutical and medical device companies, with $107,303 received in 2024. These payments were reported across 575 transactions from 37 companies. The most common payment nature is "Consulting Fee" ($329,572).
As a Medicare-enrolled provider, Patel has provided services to 881 Medicare beneficiaries, totaling 1,450 services with total Medicare billing of $110,923. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Nashville, TN
- Active Since 04/28/2009
- Last Updated 02/24/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1346484821
Products in Payments
- CALQUENCE (Drug) $136,267
- Yescarta (Drug) $55,262
- Imbruvica (Drug) $35,355
- Revlimid (Drug) $25,377
- IMBRUVICA (Drug) $24,754
- BRUKINSA (Drug) $21,695
- ADCETRIS (Biological) $13,003
- JAYPIRCA (Drug) $12,649
- Rituxan (Biological) $8,648
- JCAR017 (Drug) $8,475
- GAZYVA (Biological) $8,179
- VENCLEXTA (Drug) $7,152
- Tecartus (Drug) $6,700
- Lunsumio (Biological) $5,262
- UKONIQ (Drug) $2,475
- VENCLEXTA (Biological) $2,379
- Rituxan (Drug) $2,119
- Beleodaq (Drug) $1,950
- DARZALEX (Biological) $1,283
- Non-Covered Product (Drug) $1,000
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Nashville
Dr. Jonathan Abbas, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Kent Shih, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Alan Tan, M.d, M.D
Hematology & Oncology — Payments: $1.0M
Hematology & Oncology $1.0M
Brian Rini, Md, MD
Hematology & Oncology — Payments: $685,999
Hematology & Oncology $685,999
Jesus Berdeja, M.d, M.D
Hematology & Oncology — Payments: $572,989
Hematology & Oncology $572,989
Dr. Robert Cornell, M.d, M.D
Hematology & Oncology — Payments: $564,553
Hematology & Oncology $564,553